Tag: heart attack onglyza

On January 25, 2018, the Judicial Panel on Multidistrict Litigation (JPML) heard arguments regarding whether to centralize federal lawsuits filed by individuals who have suffered heart failure after taking the diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). Saxagliptin is part of the class of dipeptidyl peptidase-4 (DPP-4) inhibitor drugs, which are used with…